Focus on the drug release platform and glycomics
| PLATFORM | PRODUCT | POTENTIAL INDICATION | CURRENT STATUS | FORECAST MILESTONES |
|---|---|---|---|---|
 ISM
|
Risperidona ISM® | Schizophrenia |
III
I - Pre - clinical
|
Ph.II successfully completed. Start of Phase III clinical trial in May 2017 Start of Ph.I in 2nd half of 2017 |
| Letrozol ISM® | Breast cancer | |||
 Glicomics
|
Enoxaparin biosimilar |
Thromboembolic venous disease |
III
|
Registration phase |